We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Emerging Technologies Boost European IVD Markets

By Labmedica staff writers
Posted on 07 Nov 2006
The emergence and widening adoption of new technologies are boosting the revenue prospects of European in vitro diagnostics (IVD) markets.

Frost & Sullivan (Palo Alto, CA, USA), a global growth-consulting company, reported that the European IVD markets earned revenues of U.S.$6.60 billion in 2005 and estimates they will reach U.S.$9.95 billion in 2012.

"The adoption of new technologies, such as molecular and point-of-care testing, combined with the increasing trend towards laboratory automation will drive growth in the European IVD markets,” noted Frost & Sullivan research associate A.K. More...
Arun. "An emphasis on providing high quality healthcare and ensuring timely diagnosis is driving the adoption of these clinical tests and automated solutions while promoting market growth.”

Emerging markets such as molecular testing and near testing are supporting established segments such as clinical chemistry and hematology, thereby spurring market expansion. Moreover, labor shortages are pressurizing clinical laboratories to adopt high throughput and modular solutions, reinforcing growth in the market.

However, challenges still exist in the industry. Demographic changes combined with new diseases are compelling IVD manufacturers to increase their R&D investments. At the same time, competition has led to price erosion, squeezing revenue returns for market participants. In addition, the growing popularity of emerging segments could overshadow mature segments in the market.

A focused strategy will be vital for IVD manufacturers to ensure sufficient returns on investment. In the present market scenario, approaches centering on competitive pricing, new and innovative products, a broad product portfolio, and novel technologies will allow companies to gain a competitive edge.



Related Links:
Frost & Sullivan

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.